Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GUB09-145
- Development stage
- Preclinical
- Lead developer
- Gubra
- Modality
- Peptides
- Administration
- Subcutaneous
01
Overview
GUB09-145 is a long-acting, lipidated dual agonist of the glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2) receptors. Developed by Gubra, GUB09-145 is designed to mimic the physiological benefits of Roux-en-Y gastric bypass (RYGB) surgery by combining the insulinotropic and appetite-suppressing effects of GLP-1 with the intestinotrophic (gut-proliferative) effects of GLP-2. In preclinical models of obesity and diabetes, GUB09-145 has demonstrated potent effects on reducing food intake, promoting weight loss, improving glucose tolerance, and increasing small intestinal volume and mucosal surface area.
02
Targets
GLP1R (GLP-1R)GLP2R (Glucagon-like peptide 2 receptor)
Beyond the preview
Go deeper on GUB09-145.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GUB09-145.